-
2024-511832-29-00
4
2020-08-05
High risk adenocarcinoma of the prostate after radical prostatectomy
(
-
2023-509242-35-00
5
2020-07-23
HR+/HER2- early breast cancer
-
2024-516271-32-00
5
2020-06-03
Adenocarcinoma of the gastroesophageal junction (AEG type I-III)
-
2024-512682-14-00
4
2020-04-06
Non-resectable hepatocellular carcinoma (HCC)
-
2024-511577-29-01
5
2020-03-13
intermediate and high-risk rectal cancer
-
2023-506782-56-00
5
2020-03-10
RET-Mutant Medullary Thyroid Cancer
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2022-502478-18-00
4
2019-12-20
Acute Myeloid Leukemia (AML)
-
2023-503670-21-00
5
2019-08-28
Patients with newly diagnosed AML and intermediate- or adverse-risk ge
-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)
-
2023-504932-16-00
5
2019-06-04
Muscle Invasive Bladder Cancer
-
2023-508864-31-00
5
2019-04-03
Achondroplasia
-
2023-503254-12-00
5
2019-03-06
Metastatic Prostate Cancer
-
2022-502832-37-00
5
2019-03-01
Acute myeloid leukemia
-
2023-510015-19-00
5
2019-02-11
Patients with histologically or cytologically documented muscle-invasi
-
2024-514945-12-00
10
2018-09-03
locally advanced resectable adenocarcinoma of the oesophagogastric
jun
-
2024-515783-31-00
5
2018-08-24
Newly Diagnosed Multiple Myeloma
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2023-508726-10-00
5
2018-03-28
Hepatocellular Carcinoma
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2023-510444-21-00
5
2017-11-24
Neuroendocrine tumours of gastroenteric or pancreatic origin
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-505509-18-00
5
2017-07-12
mature aggressive B-cell lymphoma and leukemia in children and adolesc
-
2024-515283-31-00
6
2015-07-30
This study is designed to accept patients with varied disease origins,